REFERENCES
1. Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141:e745.
2. Hang W, Chen C, Seubert JM, Wang DW. Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. Sig Transduct Target Ther. 2020;5:287.
3. Jiang J, Shu H, Wang DW, et al. Chinese society of cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci. 2024;67:913-39.
4. Kanaoka K, Onoue K, Terasaki S, et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation. 2022;146:1425-33.
5. Moslehi JJ, Brinkley DM, Meijers WC. Fulminant myocarditis: evolving diagnosis, evolving biology, evolving prognosis. J Am Coll Cardiol. 2019;74:312-4.
6. Wei X, Fang Y, Hu H. Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis. Eur Heart J. 2020;41:2122.
8. Ammirati E, Veronese G, Brambatti M, et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2019;74:299-311.
9. Cui G, Nie J, Li H, et al. The clinicopathologic features of fulminant myocarditis. J Adv Res. 2026;81:945-53.
10. Majunke N, Haertel F, Binzenhöfer L, et al. Fulminant myocarditis: outcome predictors in an international cohort study. Eur Heart J. 2025:ehaf671.
11. Zhou N, Zhao Y, Jiang J, et al. Impact of mechanical circulatory support and immunomodulation therapy on outcome of patients with fulminant myocarditis: Chinese registry of fulminant myocarditis. Sig Transduct Target Ther. 2021;6:350.
12. Schmidt M, Ponnaiah M, Huang F, et al. Temporary mechanical support in fulminant myocarditis: prognostic factors and clinical implications from the FULLMOON study. Intensive Care Med. 2026;52:240-51.
13. Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46:3952-4041.
14. Schultheiss H, Escher F. Endomyocardial biopsy in fulminant myocarditis: need for early and accurate diagnosis to improve the outcome. Eur Heart J. 2023;44:5125-7.
15. Huang F, Ammirati E, Ponnaiah M, et al. Fulminant myocarditis proven by early biopsy and outcomes. Eur Heart J. 2023;44:5110-24.
16. Müller OJ, Heckmann MB, Ding L, et al. Comprehensive plasma and tissue profiling reveals systemic metabolic alterations in cardiac hypertrophy and failure. Cardiovasc Res. 2019;115:1296-305.
17. Wang J, He M, Li H, et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis. J Am Heart Assoc. 2022;11:e024417.
18. Nie J, Zhou L, Tian W, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Sig Transduct Target Ther. 2025;10:112.
19. Wong Y, Cheung CYY, Tang CS, et al. High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus. Cardiovasc Diabetol. 2019;18:171.
20. James SK, Lindbäck J, Tilly J, et al. Troponin-T and N-Terminal Pro-B-Type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48:1146-54.
21. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071-8.
22. Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718-25.
23. Xu G, Chen F, Zhao W, Zheng Y, Zhuang W, Yu F. Establishment and assessment of a nomogram model for predicting the risk of fulminant myocarditis: a STROBE compliant cross-sectional study. Medicine. 2021;100:e25317.
24. Erbay I, Kokturk U, Eris Gudul N, Avci A. Prognostic role of systemic immune-inflammation index versus other cardiac markers in acute myocarditis in young adults. Biomark Med. 2024;18:889-97.
25. Jenny NS, Cushman M. C-reactive protein: initiator or product of inflammation? Circ Res. 2014;114:596-7.
26. Gao R, Wang L, Bai T, Zhang Y, Bo H, Shu Y. C-reactive protein mediating immunopathological lesions: a potential treatment option for severe influenza a diseases. EBioMedicine. 2017;22:133-42.
27. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000;26:S148-52.
28. Zeller J, Bogner B, Mcfadyen J, et al. Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases. Pharmacol Ther. 2022;235:108165.
29. Yaradilmiş RM, Güneylioğlu MM, Öztürk B, et al. A novel marker for predicting fulminant myocarditis: systemic immune-inflammation index. Pediatr Cardiol. 2022;44:647-55.
30. Kangel D, Ozyılmaz İ, Ozkok S, et al. New systemic inflammatory indices as predictors of fulminant myocarditis in children. Diagnostics. 2025;15:961.
31. Wen J, Li H, Zhou Y, et al. Immunoglobin attenuates fulminant myocarditis by inhibiting overactivated innate immune response. Br J Pharmacol. 2024;182:4984-5003.
32. Li H, Chen X, Wang JJ, et al. Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis. Sig Transduct Target Ther. 2025;10:59.
33. Mangalesh S, Dudani S, Malik A. The systemic immune-inflammation index in predicting sepsis mortality. Postgrad Med. 2022;135:345-51.
34. Agus HZ, Kahraman S, Arslan C, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. J Saudi Heart Assoc. 2020;32:58-64.
35. Wang X, Wen Q, Li Y, et al. Systemic inflammation markers (SII and SIRI) as predictors of cognitive performance: evidence from NHANES 2011-2014. Front Neurol. 2025;16:1527302.
36. Tardif MR, Chapeton-Montes JA, Posvandzic A, Pagé N, Gilbert C, Tessier PA. Secretion of S100A8, S100A9, and S100A12 by neutrophils involves reactive oxygen species and potassium efflux. J Immunol Res. 2015;2015:1-16.
37. He W, Wu J, Wang D, et al. Plasma proteomics identifies S100A8/A9 as a novel biomarker and therapeutic target for fulminant myocarditis. J Adv Res. 2026;81:717-30.
38. Zhuang Y, Wang J, Li H, Chen Y, Chen C, Wang DW. Plasma siglec-5 and CD163 as novel biomarkers for fulminant myocarditis. Biomedicines. 2022;10:2941.
39. Vuchkovska A, Glanville DG, Scurti GM, et al. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells. Immunology. 2022;166:238-48.
40. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 2013;18:2352-63.
41. Zhuang Y, Zhang Z, Li H, et al. Soluble ST2 drives fulminant myocarditis progression via the IGF2R-YY1 mitochondrial axis. Eur Heart J. 2026:ehag105.
42. Hou W, Shi T, Li Y, Li W, Xu M, Peng F. Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: a retrospective observational study. Medicine. 2023;102:e34784.
43. Zhao Y, Wang Y, Zhao X, et al. cfDNA methylation detection as potential liquid biopsy of multiple organ injury in myocarditis patients. Clin Epigenet. 2025;17:106.
44. Wang J, Han B, Yi Y, et al. Expression profiles and functional analysis of plasma tRNA-derived small RNAs in children with fulminant myocarditis. Epigenomics. 2021;13:1057-75.
45. Wang W, Sun J, Li J. Serum hsa-miR-21 expression and its clinical value in pediatric patients with fulminant myocarditis. J Pediatr. 2025;101:101409.
46. Nie X, He M, Wang J, et al. Circulating miR-4763-3p is a novel potential biomarker candidate for human adult fulminant myocarditis. Mol Ther Methods Clin Dev. 2020;17:1079-87.
47. Huang S, He S, Xiao F, Zhou Y, Lyu S. Circular RNA encoded by PPARG in the peripheral blood and a lipopolysaccharide-induced cardiomyocyte inflammation model is identified as a marker of fulminant myocarditis. Eur J Med Res. 2025;30:72.
48. Chen JH, He J, Zhou R, Zheng N. [Expression and Significance of Circulating microRNA-29b in Adult Fulminant Myocarditis]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022;44:102-9.
49. Zhao C, Long X, Wang K, Tian S, Li Y, Zhang W. High-throughput untargeted metabolomic profiling of urinary biomarkers in acute myocarditis patients: a cross-sectional study. Sci Rep. 2025;15:9254.
50. Chen Y, Liu X, Hong C, et al. Metabolic profiling reveals diagnostic biomarkers for distinguishing myocarditis from acute myocardial infarction. Cardiovasc Ther. 2025;2025:6292099.
51. Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Investig. 2021;131:e145186.
52. Ramayya T, Mitchell JD, Hartupee JC, et al. Delayed diagnosis and recovery of fulminant immune checkpoint inhibitor-associated myocarditis on VA-ECMO support. JACC CardioOncol. 2022;4:722-6.
53. Wang S, Xu H, Guo Z, et al. Association of inflammatory index with the severity of disease in patients with acute myocarditis: a retrospective observational study. Front Endocrinol. 2025;16:1597427.
54. Bang V, Ganatra S, Shah SP, et al. Management of patients with giant cell myocarditis: JACC review topic of the week. J Am Coll Cardiol. 2021;77:1122-34.
55. Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329:1098.
56. Tong Z, Yan X, Chen T, et al. Single-cell multi-omics identifies specialized cytotoxic and migratory CD8+ effector T cells in acute myocarditis. Circulation. 2025;152:1003-22.
57. Liu K, Zhang L, Duan X, et al. Peripheral immune imbalance in pediatric fulminant myocarditis revealed by single-cell sequencing and plasma proteomics. Genes Immun. 2025;26:394-412.
58. Li H, Zhang M, Zhao Q, et al. Self-recruited neutrophils trigger over-activated innate immune response and phenotypic change of cardiomyocytes in fulminant viral myocarditis. Cell Discov. 2023;9:103.
59. Won T, Song EJ, Kalinoski HM, Moslehi JJ, Čiháková D. Autoimmune myocarditis, old dogs and new tricks. Circ Res. 2024;134:1767-90.
60. Ma P, Liu J, Qin J, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation. 2024;149:48-66.
61. Veronese G. Fulminant myocarditis: characteristics, treatment, and outcomes. Anatol J Cardiol. 2018;19:279-86.
62. D’ettore N, Eghbalzadeh K, Oezkur M, Bertoldi LF, Bossard M, Pappalardo F. Diagnosis and management of patients with fulminant myocarditis. Eur Heart J Suppl. 2025;27:iv23-30.
63. Wei X, Fang Y, Hu H. Consideration on pathogen of viral fulminant myocarditis. Eur Heart J. 2020;41:2120.
64. Ma J, Li Y, Li P, et al. S100A8/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure. Nat Commun. 2024;15:2701.
65. He R, Yue G, Dong M, Wang J, Cheng C. Sepsis biomarkers: advancements and clinical applications—a narrative review. Int J Mol Sci. 2024;25:9010.
66. Asta L, Pisano C, Sbrigata A, Raffa GM, Scola L, Balistreri CR. Biomarkers in heart failure: a review and a wish. Int J Mol Sci. 2025;26:8046.
